A Study for Patients with Hypereosinophilic Syndrome (HES)
Official Title
A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)
Purpose
The purpose of this study is to see if benralizumab (biologic drug), given as injections under the skin, can help control your Hypereosinophilic Syndrome (HES) better if it is added to available standard of care HES medications which you may be currently taking.
HES (Hypereosinophilic Syndrome) is a disease characterized by high levels of eosinophils (a particular type of white blood cell) in your blood and a build-up of eosinophils in some organs and tissues (like skin, heart, lungs, intestines or others) causing their dysfunction.
The duration of the study will last 18 months.
Could this study be right for you?
- Eosinophil (a type of white blood cells) count ≥ 1000 cells/μL at screening
- Documented diagnosis of Hypereosinophilic Syndrome (HES)
- History of persistent eosinophilia >1500 cells/μL (at least 2 examinations, interval ≥1 month)
- End organ manifestations attributable to the eosinophilia
Inclusion and Exclusion Criteria varies, please contact Study Coordinator for more information.